Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Charlene Bui

Family Medicine Wichita, KS Physician Assistant

NPI 1144258484 CMS profile 509725

7111 E 21St Street N, Suite A, Wichita, KS 67206

Open in the dashboard

General payments

$8,778

605 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charlene Bui of Wichita, KS is reported in the CMS Open Payments database as having received $8,778 across 605 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,168 73
2024 General $1,436 72
2023 General $1,260 99
2022 General $2,125 161
2021 General $2,789 200

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charlene Bui
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Charlene Bui were reported at $1,168. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Charlene Bui Family Medicine median Middle half National median
2019 $0 $150 $41–$543 $163
2020 $0 $120 $32–$415 $114
2021 $2,789 $137 $35–$551 $132
2022 $2,125 $137 $37–$512 $149
2023 $1,260 $149 $42–$545 $160
2024 $1,436 $156 $44–$560 $164
2025 $1,168 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,240 146 payments
  2. GlaxoSmithKline, LLC. $754 29 payments
  3. Lilly USA, LLC $683 70 payments
  4. Supernus Pharmaceuticals, Inc. $652 14 payments
  5. Novo Nordisk Inc $550 56 payments
  6. Janssen Pharmaceuticals, Inc $412 37 payments
  7. Pfizer Inc. $358 23 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $317 20 payments
  9. Amgen Inc. $295 24 payments
  10. Sanofi-Aventis U.S. LLC $289 17 payments
  11. Other $3,229 169 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,778 605 payments
Products named General payments · program years 2021–2025
  1. Qelbree $551 8 payments
  2. SHINGRIX $500 17 payments
  3. GEMTESA $404 17 payments
  4. JARDIANCE $384 43 payments
  5. Ozempic $382 31 payments
  6. XARELTO $373 33 payments
  7. LINZESS $334 44 payments
  8. QULIPTA $330 33 payments
  9. UBRELVY $323 36 payments
  10. RYBELSUS $319 27 payments
  11. Other $7,629 549 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

605 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record